Imatinib Hcs

Imatinib, the active ingredient in Imatinib Hcs, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of certain hematologic and solid tumours, including chronic myeloid leukemia, gastrointestinal stromal tumours, and Philadelphia chromosome‑positive acute lymphoblastic leukaemia.

GNH USA supplies Imatinib Hcs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance. Our distribution network ensures timely delivery and adherence to local import requirements.

Imatinib is a tyrosine kinase inhibitor used in oncology to target specific molecular pathways. - Chronic myeloid leukemia: reduces disease burden by inhibiting BCR‑ABL driven proliferation and inducing cytogenetic responses. - Gastrointestinal stromal tumor: controls tumor growth by blocking c‑KIT signaling, leading to disease stabilization. - Philadelphia chromosome‑positive acute lymphoblastic leukaemia: improves remission rates through BCR‑ABL inhibition and facilitates subsequent chemotherapy effectiveness.

Imatinib may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset, often occurring early in therapy. - Diarrhea: loose stools that may be transient but can require hydration. - Edema: peripheral swelling, especially of the ankles and feet. - Fatigue: persistent tiredness affecting daily activities. - Muscle cramps: involuntary muscle tightening, commonly in the calves. - Rash: skin redness or mild eruption, usually self‑limiting.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or clinically significant liver injury. - Cardiotoxicity: congestive heart failure or reduced left‑ventricular function. - Severe neutropenia: marked decrease in neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels leading to bleeding or bruising. - Pulmonary arterial hypertension: increased pressure in lung arteries causing shortness of breath. - Anaphylaxis: severe allergic reaction that may be life‑threatening.

When prescribing Imatinib, clinicians should consider several precautionary measures to ensure patient safety. - Baseline assessment: obtain complete blood count, liver function tests and cardiac evaluation before initiation. - Monitoring: perform regular CBC, hepatic panels and renal function during therapy. - Drug interactions: review concomitant medications for CYP3A4 substrates or inhibitors. - Pregnancy and lactation: avoid use unless potential benefit justifies potential risk; discuss with specialist. - Contraindications: do not use in patients with known hypersensitivity to imatinib or its excipients. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct light.

Imatinib can affect and be affected by other medicines; awareness of key interactions helps manage therapy safely.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib plasma levels, raising toxicity risk. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce imatinib exposure, compromising efficacy.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors, antacids): can lower imatinib absorption; separate dosing by at least 2 hours. - Warfarin: imatinib may enhance anticoagulant effect; monitor INR closely. - CYP2C8 substrates (e.g., paclitaxel): potential altered metabolism; adjust dose if needed. - Vaccines: live attenuated vaccines may have reduced efficacy; consider timing.